FP
REGN icon

FDO Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

FDO Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,985
Closed -$2.23M – 246
2017
Q3 		$2.23M Buy
+4,985
New +$2.37M 0.89% 27

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

FDO Partners's REGN Position: Q4 2017 in Review

FDO Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 4,985 shares — an estimated $2.23M sold.

FDO Partners first reported a position in REGN in Q3 2017 and held it in 1 quarter. The position peaked at $2.23M in Q3 2017. 638 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • FDO Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • FDO Partners sold 4,985 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $2.23M.
  • FDO Partners first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • FDO Partners's Regeneron Pharmaceuticals position peaked at $2.23M in Q3 2017.
  • 638 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on FDO Partners's 13F filing for Q4 2017, filed 13 Feb 2018.